Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Wang, Hong ^a,b   Zhang, Bingfeng ^a,b   Chen, Dan ^a,b   Xia, Wenying ^a,b   Zhang, Jiexin ^a,b   Wang, Fang ^a,b   Xu, Jian ^a,b   Zhang, Yan ^a,b   Zhang, Meijuan ^a,b   Zhang, Lixia ^a,b   Lu, Yachun ^a,b   Geng, Yan ^a,b   Huang, Peijun ^a,b   Huang, Puwen ^a   Pan, Shiyang ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b National Key Clinical Department of Laboratory Medicine   (China)

Author keywords

Advanced lung cancer; APC; Circulating DNA; Hypermethylation; RASSF1A

Indexed keywords

APC PROTEIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DNA; NEURON SPECIFIC ENOLASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

A549 CELL LINE; ADULT; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APC GENE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DNA DETERMINATION; DNA METHYLATION; DYSPEPSIA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART PALPITATION; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; INNER EAR DISEASE; LIVER TOXICITY; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; MTT ASSAY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NONHUMAN; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT MONITORING; PHLEBITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASSF1A GENE; REAL TIME MONITORING; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; TINNITUS; TREATMENT OUTCOME; TUMOR RESPONSE; VALIDATION STUDY; VERTIGO; VOMITING;

EID: 84946205400     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0150-9     Document Type: Article

References (40)

1. Mascaux C, Peled N, Garg K, Kato Y, Wynes MW, Hirsch FR. Early detection and screening of lung cancer. Expert Rev Mol Diagn. 2010;10:799-815.
2. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012;18:2391-401.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-94.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
5. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007;2:327-43.
6. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las PR, et al. 14-3-3σmethylation in pretreatment serum circulating DNA of cisplatin-plusgemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105-12.
7. Allingham-Hawkins D, Lea A, Levine S. ERCC1 expression analysis to guide therapy in non-small cell lung cancer. PLoS Curr. 2010;2:RRN1202.
8. O’Byrne KJ, Barr MP, Gray SG. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers. 2011;3:1426-53.
9. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008;7:1780-94.
10. Jain KK. Textbook of personalized medicine. New York: Springer; 2009. p. 186.
11. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635:105-17.
12. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, et al. Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer. 2010;116:1918-25.
13. Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Plasma DNA level in predicting therapeutic efficacy in advanced non-small cell lung cancer. Eur Respir J. 2010;36:885-92.
14. Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer. 2010;116:1674-80.
15. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med. 2010;10:142-65.
16. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26:2442-9.
17. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099-105.
18. Shepherd FA. Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol. 2008;26:2426-7.
19. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998;62:768-75.
20. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659-65.
21. Hsu HS, Chen TP, Hung CH, Wen CK, Lin RK, Lee HC, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer. 2007;110:2019-26.
22. Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323-31.
23. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118-28.
24. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 2006,12:7329-38.
25. Toyota M, Suzuki H, Yamashita T, Hirata K, Imai K, Tokino T, et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci. 2009;100:787-91.
26. Ramírez JL, Salazar MF, Gupta J, Sánchez JM, Taron M, Sanchez-Ronco M, et al. Methylation patterns and chemosensitivity in NSCLC. Adv Exp Med Biol. 2006;587:195-209.
27. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer. 2007;56:115-23.
28. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010;126:1630-9.
29. Guo S, Tan L, Pu W, Wu J, Xu K, Wu J, et al. Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer. Clin Epigenetics. 2014;6(1):5.
30. Pesek M, Kopeckova M, Benesova L, Meszarosova A, Mukensnabl P, Bruha F, et al. Clinical significance of hypermethylation status in NSCLC: evaluation of a 30-gene panel in patients with advanced disease. Anticancer Res. 2011;31:4647-52.
31. Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, et al. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with genderand histologic type. Lung Cancer. 2010;69:172-9.
32. Gao L, Xie E, Yu T, Chen D, Zhang L, Zhang B, et al. Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with undetermined solitary pulmonary nodules. J Thorac Dis. 2015;7:422-32.
33. Pan SY, Xie EF, Shu YQ, Gao L, Zhang LX, Chen D, et al. Methylation quantification of adenomatous polyposis coli (APC) gene promoter in plasma of lung cancer patients. Ai Zheng. 2009;28:384-9.
34. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 2002;62:371-5.
35. Rykova EY, Skvortsova TE, Laktionov PP, Tamkovich SN, Bryzgunova OE, Starikov AV, et al. Investigation of tumor-derived extracellular DNA in blood of cancer patients by methylation-specific PCR. Nucleosides Nucleotides Nucleic Acids. 2004;23:855-9.
36. Begum S, Brait M, Dasgupta S, Ostrow KL, Zahurak M, Carvalho AL, et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res. 2011;17:4494-503.
37. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 2011;303:21-8.
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
39. Pan S, Xia W, Ding Q, Shu Y, Xu T, Geng Y, et al. Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer ? Biomed Pharmacother. 2012;66:131-7.
40. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci. 1996;93:9821-6.